Genotype of 88 Toxoplasma gondii Isolates Associated with Toxoplasmosis in Immunocompromised Patients and Correlation with Clinical Findings
Genotype of 88 Toxoplasma gondii Isolates Associated with Toxoplasmosis in Immunocompromised Patients and Correlation with Clinical Findings
复制标题
DOI：
10.1086/597477
复制
发表时间：
2009-04-15
影响因子：
6.4
通讯作者：
Villena, Isabelle
中科院分区：
文献类型：
--
作者：
Ajzenberg, Daniel;Yera, Helene;Villena, Isabelle
我们报告了88例免疫功能低下患者样本中刚地弓形虫分离物的基因分型分析，以及临床和流行病学数据。这些样本大部分是由弓形虫生物资源中心在法国收集的。缺乏特异性抗弓形虫治疗、肺弓形虫病和累及多器官是该患者组死亡的3个主要危险因素。6个微卫星标记的基因分型结果显示，在欧洲获得弓形虫感染的患者中，II型分离株占主导地位。非II型分离株包括13种不同的基因型，主要收集自欧洲以外获得弓形虫病的患者。III型是患者中第二常见的基因型，而I型在我们的人群中很少见。从撒哈拉以南非洲（基因型非洲1和非洲2）和法属西印度群岛（基因型加勒比1）获得感染的不同患者中反复发现三种非原型基因型。当根据免疫抑制的潜在原因、感染部位或结果对患者进行分层时，基因型的分布（II型与非II型）没有显著差异。我们得出结论，在免疫功能低下的患者中，宿主因素比寄生虫因素更能影响患者对弓形虫病的抗性或易感性。
We report the genotyping analysis of Toxoplasma gondii isolates in samples collected from 88 immunocompromised patients, along with clinical and epidemiological data. Most of these samples were collected in France during the current decade by the Toxoplasma Biological Resource Center. Lack of specific anti-Toxoplasma treatment, pulmonary toxoplasmosis, and involvement of multiple organs were the 3 main risk factors associated with death for this patient group. Genotyping results with 6 microsatellite markers showed that type II isolates were predominant among patients who acquired toxoplasmic infection in Europe. Non-type II isolates included 13 different genotypes and were mainly collected from patients who acquired toxoplasmosis outside Europe. Type III was the second most common genotype recovered from patients, whereas type I was rare in our population. Three nonarchetypal genotypes were repeatedly recovered from different patients who acquired the infection in sub-Saharan Africa (genotypes Africa 1 and Africa 2) and in the French West Indies (genotype Caribbean 1). The distribution of genotypes (type II vs. non-type II) was not significantly different when patients were stratified by underlying cause of immunosuppression, site of infection, or outcome. We conclude that in immunocompromised patients, host factors are much more involved than parasite factors in patients' resistance or susceptibility to toxoplasmosis.